business
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute
Key takeaways
- Supreme Court Rejects Care Dx A’s Appeal in Natera, Inc.
- Supreme Court declined to hear Care Dx's appeal in its false-advertising dispute with Natera, Inc.
- Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test.
U.S. Supreme Court Rejects Care Dx A’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute Fatima Gulzar Mon, June 29, 2026 at 2:58 AM GMT+7 1 min read NTRA Natera, Inc. (NASDAQ:NTRA) is among the Best Healthcare Stocks.
On June 1, Reuters reported that the U.S. Supreme Court declined to hear Care Dx's appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied Care Dx damages over claims involving kidney transplant tests.
Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test. It offered no explanation for the decision.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop